Jin Medical CEO Fireside Chat

Core Insights - Jin Medical International Ltd. is focusing on strategic priorities and long-term growth considerations as discussed by CEO Dr. Erqi Wang during a recent CEO Fireside Chat [1][2] Group 1: Reverse Split - The company is considering a reverse stock split to regain compliance with Nasdaq's listing standards and to realign its capital structure with long-term fundamentals [3][4] Group 2: Strategic Plan for Long-Term Value Creation - The company emphasizes clear market communication, disciplined capital allocation, and a long-term perspective in its operational focus [5][6][7] Group 3: 2026–2027 Outlook - The primary objectives for 2026 and 2027 include a disciplined approach to growth, prioritizing repeatable returns and operational stability over rapid, unsustainable growth [7] Group 4: Operating Leverage - Opportunities for improving efficiency lie in broader commercialization, manufacturing scale-up, and cost normalization, with significant potential in manufacturing efficiency and product mix optimization [8][9] Group 5: Chuzhou New Factory – Strategic Importance - The Chuzhou facility is a key investment expected to enhance capacity, automation, and competitiveness, with full production capacity anticipated by the end of April 2026 [10][11] Group 6: Industry Outlook - The industry is expected to experience strong demand driven by aging populations and rising healthcare quality expectations, alongside a shift towards higher compliance and technology integration standards [13] Group 7: US–China Relations & Risk Management - The company is managing geopolitical risks through supply chain diversification and regional manufacturing flexibility to ensure resilience against external policy changes [14][15]